Search

Your search keyword '"Goldenberg, Neil A."' showing total 1,144 results
Start Over Author "Goldenberg, Neil A."
1,144 results on '"Goldenberg, Neil A."'

13. Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury

Author

Kayagaki, Nobuhiko, Stowe, Irma B., Alegre, Kamela, Deshpande, Ishan, Wu, Shuang, Lin, Zhonghua, Kornfeld, Opher S., Lee, Bettina L., Zhang, Juan, Liu, John, Suto, Eric, Lee, Wyne P., Schneider, Kellen, Lin, WeiYu, Seshasayee, Dhaya, Bhangale, Tushar, Chalouni, Cecile, Johnson, Matthew C., Joshi, Prajakta, Mossemann, Jan, Zhao, Sarah, Ali, Danish, Goldenberg, Neil M., Sayed, Blayne A., Steinberg, Benjamin E., Newton, Kim, Webster, Joshua D., Kelly, Ryan L., and Dixit, Vishva M.

Published
2023
Full Text
View/download PDF

29. Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium

Author

Abrams, Christina M., Jaffray, Julie, Stillings, Amy, Branchford, Brian R., Young, Guy, Goldenberg, Neil A., Abajas, Yasmina L., Fargo, John, Crary, Shelly, Kumar, Riten, Woods, Gary, Narang, Shalu, Cooper, James, Silvey, Mike, Garland, Kate, Mahajerin, Arash, Luchtman‐Jones, Lori, Torres, Marcela, Wright, Jordan, Pahl, Kristy, Armstrong, Katherine, Braunreiter, Chi, Bakeer, Nihal, Sochet, Anthony, Hogan, Marie, Gupta, Shveta, Knoll, Christine, Hege, Kerry, Schaefer, Beverly, Panigrahi, Arun, Thornburg, Courtney, Shimano, Kristin, Ahuja, Sanjay, Weyand, Angela, Boucher, Alexander, Abajas, Yasmina, Subbaswamy, Anjali, Khan, Osman, Druzgal, Colleen, Maida, Deanna, Wheeler, Allison, Malec, Lynn, Branchford, Brian, Kucine, Nicole Elena, and Prozora, Stephanie

Published
2022
Full Text
View/download PDF

31. Practical considerations and consensus opinion for children’s hospital–based inpatient hemostasis and thrombosis (HAT) consultative services: Communication from the ISTH SSC Subcommittee on Pediatric/Neonatal Thrombosis and Hemostasis

Author

Woods, Gary M., Raffini, Leslie, Brandão, Leonardo R., Jaffray, Julie, Branchford, Brian R., Ng, Christopher J., Sartain, Sarah E., Pak, Jennifer, Male, Christoph, Zia, Ayesha, Rizzi, Mattia, Sirachainan, Nongnuch, Faustino, Edward Vincent S., Carpenter, Shannon L., and Goldenberg, Neil A.

Published
2022
Full Text
View/download PDF

33. Methods, precision, and analytical sensitivity of a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction.

Author

Bruzek, Steven, Betensky, Marisol, Sochet, Anthony A., Goldenberg, Neil A., and Ignjatovic, Vera

Subjects
PEARSON correlation (Statistics), T-test (Statistics), TISSUE plasminogen activator, DESCRIPTIVE statistics, BLOOD coagulation tests, FIBRINOLYSIS, BLOOD plasma, CONFIDENCE intervals, SENSITIVITY & specificity (Statistics), COVID-19
Abstract

Introduction: Fibrinolysis is a critical aspect of the hemostatic system, with assessment of fibrinolytic potential being critical to predict bleeding and clotting risk. We describe the method for a novel low‐plasma‐volume assay of fibrinolytic capacity utilizing the euglobulin fraction (the "modified mini‐euglobulin clot lysis assay [ECLA]"), its analytic sensitivity to alterations in key fibrinolytic substrates/regulators, and its initial applications in acute and convalescent disease cohorts. Methods: The modified mini‐ECLA requires 50 μL of plasma, a maximal read time of 3 h (with most results available within 60 min), and is entirely performed in a 96‐well microplate. Assay measurements were obtained in a variety of commercial control and deficient plasmas representing clinically relevant hypo‐ and hyperfibrinolytic states, and in three distinct adolescent cohorts with acute or convalescent illness: critically ill, following endotracheal intubation; acute COVID‐19‐related illness; and ambulatory, 3 months following a venous thromboembolic event. Results: In 100% and 75% deficient plasmas, hypofibrinolysis for plasminogen‐deficient, fibrinolysis for alpha‐2‐antiplasmin‐deficient, and hyperfibrinolysis for plasminogen activator inhibitor‐1‐deficient plasmas were observed. Conclusion: The modified mini‐ECLA Clot Lysis Time Ratio ("CLTR") demonstrated moderate‐strength correlations with the Clot Formation and Lysis (CloFAL) assay, is analytically sensitive to altered fibrinolytic states in vitro, and correlates with clinical outcomes in preliminarily‐studied patient populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Invasive Mechanical Ventilation and Risk of Hospital-Acquired Venous Thromboembolism.

Author

Havlicek, Elizabeth E., Palumbo, Jamie, Soto-Campos, Gerardo, Goldenberg, Neil A., and Sochet, Anthony A.

Subjects
THROMBOEMBOLISM prevention, THROMBOEMBOLISM risk factors, RISK assessment, NECK, COMMUNICABLE diseases, CRITICALLY ill, PATIENTS, DEATH, T-test (Statistics), EXTRACORPOREAL membrane oxygenation, VEINS, EXTREMITIES (Anatomy), LOGISTIC regression analysis, QUESTIONNAIRES, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, HOSPITAL mortality, DISEASE prevalence, CHI-squared test, MANN Whitney U Test, TREATMENT duration, OPERATIVE surgery, LONGITUDINAL method, PEDIATRICS, TRACHEA intubation, ODDS ratio, ARTIFICIAL respiration, THROMBOEMBOLISM, INTENSIVE care units, RESEARCH, PERIPHERALLY inserted central catheters, CENTRAL venous catheters, LUNG diseases, CONFIDENCE intervals, LENGTH of stay in hospitals, DATA analysis software, DISEASE incidence, ASTHMA, COMORBIDITY, NONPARAMETRIC statistics, RHEUMATISM, CHILDREN
Abstract

BACKGROUND: This study sought to estimate the overall cumulative incidence and odds of Hospital-acquired venous thromboembolism (VTE) among critically ill children with and without exposure to invasive ventilation. In doing so, we also aimed to describe the temporal relationship between invasive ventilation and hospital-acquired VTE development. METHODS: We performed a retrospective cohort study using Virtual Pediatric Systems (VPS) data from 142 North American pediatric ICUs among children < 18 y of age from January 1, 2016-December 31, 2022. After exclusion criteria were applied, cohorts were identified by presence of invasive ventilation exposure. The primary outcome was cumulative incidence of hospital-acquired VTE, defined as limb/neck deep venous thrombosis or pulmonary embolism. Multivariate logistic regression was used to determine whether invasive ventilation was an independent risk factor for hospital-acquired VTE development. RESULTS: Of 691,118 children studied, 86,922 (12.4%) underwent invasive ventilation. The cumulative incidence of hospital-acquired VTE for those who received invasive ventilation was 1.9% and 0.12% for those who did not (P < .001). The median time to hospital-acquired VTE after endotracheal intubation was 6 (interquartile range 3-14) d. In multivariate models, invasive ventilation exposure and duration were each independently associated with development of hospital-acquired VTE (adjusted odds ratio 1.64 [95% CI 1.42-1.86], P < .001; and adjusted odds ratio 1.03 [95% CI 1.02-1.03], P < .001, respectively). CONCLUSIONS: In this multi-center retrospective review from the VPS registry, invasive ventilation exposure and duration were independent risk factors for hospital-acquired VTE among critically ill children. Children undergoing invasive ventilation represent an important target population for risk-stratified thromboprophylaxis trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Reporting preclinical anesthesia study (REPEAT): Evaluating the quality of reporting in the preclinical anesthesiology literature.

Author

Fergusson, Dean A, Avey, Marc T, Barron, Carly C, Bocock, Mathew, Biefer, Kristen E, Boet, Sylvain, Bourque, Stephane L, Conic, Isidora, Chen, Kai, Dong, Yuan Yi, Fox, Grace M, George, Ronald B, Goldenberg, Neil M, Gragasin, Ferrante S, Harsha, Prathiba, Hong, Patrick J, James, Tyler E, Larrigan, Sarah M, MacNeil, Jenna L, Manuel, Courtney A, Maximos, Sarah, Mazer, David, Mittal, Rohan, McGinn, Ryan, Nguyen, Long H, Patel, Abhilasha, Richebé, Philippe, Saha, Tarit K, Steinberg, Benjamin E, Sampson, Sonja D, Stewart, Duncan J, Syed, Summer, Vella, Kimberly, Wesch, Neil L, Lalu, Manoj M, and Canadian Perioperative Anesthesia Clinical Trials Group

Subjects
Canadian Perioperative Anesthesia Clinical Trials Group, Animals, Pain, Analgesics, Drug Evaluation, Preclinical, Databases, Factual, Guidelines as Topic, Research Report, Databases, Factual, Drug Evaluation, Preclinical, General Science & Technology
Abstract

Poor reporting quality may contribute to irreproducibility of results and failed 'bench-to-bedside' translation. Consequently, guidelines have been developed to improve the complete and transparent reporting of in vivo preclinical studies. To examine the impact of such guidelines on core methodological and analytical reporting items in the preclinical anesthesiology literature, we sampled a cohort of studies. Preclinical in vivo studies published in Anesthesiology, Anesthesia & Analgesia, Anaesthesia, and the British Journal of Anaesthesia (2008-2009, 2014-2016) were identified. Data was extracted independently and in duplicate. Reporting completeness was assessed using the National Institutes of Health Principles and Guidelines for Reporting Preclinical Research. Risk ratios were used for comparative analyses. Of 7615 screened articles, 604 met our inclusion criteria and included experiments reporting on 52 490 animals. The most common topic of investigation was pain and analgesia (30%), rodents were most frequently used (77%), and studies were most commonly conducted in the United States (36%). Use of preclinical reporting guidelines was listed in 10% of applicable articles. A minority of studies fully reported on replicates (0.3%), randomization (10%), blinding (12%), sample-size estimation (3%), and inclusion/exclusion criteria (5%). Statistics were well reported (81%). Comparative analysis demonstrated few differences in reporting rigor between journals, including those that endorsed reporting guidelines. Principal items of study design were infrequently reported, with few differences between journals. Methods to improve implementation and adherence to community-based reporting guidelines may be necessary to increase transparent and consistent reporting in the preclinical anesthesiology literature.

Published
2019

38. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

Author

Whitworth, Hilary, Sartain, Sarah E., Kumar, Riten, Armstrong, Katherine, Ballester, Lance, Betensky, Marisol, Cohen, Clay T., Diaz, Rosa, Diorio, Caroline, Goldenberg, Neil A., Jaffray, Julie, Keegan, Jacquelyn, Malone, Kendra, Randolph, Adrienne G., Rifkin-Zenenberg, Stacey, Leung, Wendy Seto, Sochet, Anthony, Srivaths, Lakshmi, Zia, Ayesha, and Raffini, Leslie

Published
2021
Full Text
View/download PDF

43. Dosing, Monitoring, Blood Product Utilization, and Thromboembolic Complications of Four-Factor Prothrombin Complex Concentrate as Part of an Institutional Protocol in Pediatric Cardiac Surgery: A Retrospective Cohort Study.

Author

Kiskaddon, Amy L., Goldenberg, Neil A., Fierstein, Jamie L., Miller, Alexandra, Quintessenza, James A., and Kartha, Vyas M.

Subjects
*MEDICAL care use, *PEDIATRIC surgery, *CARDIAC surgery, *THROMBOEMBOLISM, *PROTHROMBIN, *TUBE feeding, *CHEST tubes
Abstract

Pediatric cardiac surgery patients are predisposed to blood loss. Blood product administration can lead to complications. Prothrombin complex concentrates (PCCs) offer potential advantages of factor composition, small volume, decreased immunogenicity/infectious risks, and accessibility. The objective of this study was to describe dosing, monitoring, blood product utilization, and thromboembolic complications of administering four-factor PCC (4F-PCC) in pediatric cardiac surgery. We performed a retrospective review of patients aged <18 years undergoing cardiac surgery from June 2020 to May 2022 (inclusive) who received 4F-PCC. Outcomes of interest included 4F-PCC dosing (units/kg) and number of doses administered, chest tube output, blood product administration, donor exposure, length of stay, and thromboembolic events. Eighty-six patients met eligibility criteria. The median (range) age and weight were 0.37 (0.01–16.3) years and 5.3 (1.6–98) kg, respectively. Median (range) total 4F-PCC dose per patient was 25 (9.2–50) units/kg, with 6 patients (7%) receiving a total of two doses. Median (range) 24-hour postoperative packed red blood cells, platelet, plasma, and cryoprecipitate administration volumes were 0 (0–2.57) mL/kg/24 h, 0 (0–1.09), 0 (0–2.64), and 0 (0–0.28 mL/kg/24 h), respectively. Median (range) length of stay and 24-hour postoperative chest tube output were 10 (6–26) days and 1.1 (0.1–4.2) mL/kg/h, respectively. Two (2%) patients experienced a thromboembolic event within 30 days of 4F-PCC administration. These retrospective findings suggest no worsening of hemostatic parameters, a mild median improvement in fibrinogen, low blood product utilization, and low thromboembolism rates following 4F-PCC use in pediatric cardiac surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results